Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal

Executive Summary

CEO Heather Bresch defended her company’s controversial decision to raise the price of the allergy medicine to $600 during the Forbes Healthcare Summit and even took questions from fellow pharma insiders like “Why did you ruin it?”

Advertisement

Related Content

J&J Outlines Pricing Transparency Plan, Will Others Follow?
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
What Does 2017 Hold For Pharma?
Lilly’s Insulin Discounts Target High-Deductible Insurance Gaps
Mylan Plans Workforce Reduction After M&A And Price Scandal
Trump Win Is False Security For Drug Makers, Allergan CEO Warns
Investors Relieved As Mylan Settlement Avoids Investigation
How Many Pricing Hearings Add Up To Action On Pricing Transparency?
EpiPen Price Story Highlights Growing Impact Of Drug Deductibles
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel